[Efficacy of albendazole immunoliposome against echinococcosis granulosus in mice].

OBJECTIVE: To evaluate the effect of albendazole immunoliposome (IL-Alb) against Echinococcus granulosus. METHODS: Mice infected with protoscolices of E. granulosus were divided into five groups. Four groups were treated with albendazole (Alb), albendazole liposome (L-Alb), albendazole sulfoxide liposome (L-Albso), and IL-Alb respectively at a dosage of 100 mg (Alb)/(kg.d) x 5 d for 3 courses. The fifth group was established as control. The major criteria for evaluating the effects included a reduction rate of E. granulosus tissue wet weight, histopathological examination of the cysts by both light microscopy and electron-microscopy, and the content of albendazole-sulfoxide in cysts detected by HPLC. RESULTS: The efficacy of albendazole immunoliposome was significantly higher than that of albendazole liposome, and much higher than that of albendazole. The reduction rates of cyst tissue weight of IL-Alb group, L-Alb group and Alb group were 91.5%, 80.3%, 61.2% respectively as compared to control group; the concentration of Albso in cyst tissue of the above groups were 5.15 micrograms/g, 2.18 micrograms/g, 0.76 microgram/g respectively (P < 0.01). The histopathological damages of cysts were also found most severely in the group of IL-Alb. CONCLUSION: Immunoliposome as a targeting carrier may significantly strengthen the therapeutic effect of albendazole on echinococcosis granulosus.